07:00 , May 6, 2013 |  BioCentury  |  Finance

Keep it small

Atlas Venture decided to stay small with its oversubscribed ninth fund, raising $265 million that will primarily go towards seeding biotech and technology startups. Absent from the shopping list are young diagnostic companies, as the...
07:00 , Oct 10, 2011 |  BC Week In Review  |  Company News

Exosome Diagnostics management update

Exosome Diagnostics Inc. , New York, N.Y.   Business: Diagnostic, Cancer   Hired: Michael Donovan as CMO, formerly chief scientific officer of Aureon Biosciences Inc. ; and David Okrongly as COO, formerly president and CEO...
00:33 , Oct 5, 2011 |  BC Extra  |  Company News

Exosome expands management team

Exosome Diagnostics Inc. (New York, N.Y.) hired Michael Donovan as CMO and David Okrongly as COO. Donovan is the former CSO of Aureon BioSciences Inc. (Yonkers, N.Y.), while Okrongly is the former CEO of Quanterix...
08:00 , Dec 7, 2009 |  BioCentury  |  Finance

Ebb & Flow

The latest follow-on from Human Genome Sciences Inc. (NASDAQ:HGSI) will increase its cash to around $1.1 billion, more than enough to get Benlysta belimumab to market for systemic lupus erythematosus. Indeed, if all goes well,...
07:00 , Aug 31, 2009 |  BC Week In Review  |  Company News

Aureon Laboratories Inc. management update

Aureon Laboratories Inc. , Yonkers, N.Y.   Business: Diagnostic, Pharmacogenetics   Promoted: Robert Shovlin to CEO from COO while remaining president; he replaces Vijay Aggarwal, who will remain a director  ...
07:00 , Jul 24, 2008 |  BC Innovations  |  Tools & Techniques

Imaging Prostate Cancer Metastasis

Determining the status of lymph node metastasis in prostate cancer is important for deciding treatment options, but current techniques for detecting metastasis are imprecise and invasive. A paper published in Nature Medicine describes a noninvasive...
07:00 , Jun 16, 2008 |  BC Week In Review  |  Company News

Aureon Laboratories Inc., University of Texas M. D. Anderson Cancer Center deal

The company and the center will collaborate to discover biomarkers associated with disease progression and overall survival in non-small cell lung cancer (NSCLC). Aureon will provide its Systems Pathology platform and the center will provide...
07:00 , May 26, 2008 |  BC Week In Review  |  Company News

Aureon Biosciences Corp. sales and marketing update

Aureon launched its Prostate Px+ test to predict prostate cancer progression and disease recurrence at the time of diagnosis. Aureon Biosciences Corp. , Yonkers, N.Y.   Business: Diagnostic  ...
07:00 , Mar 24, 2008 |  BC Week In Review  |  Company News

Aureon Laboratories Inc. management update

Aureon Laboratories Inc. , Yonkers, N.Y.   Business: Diagnostic, Pharmacogenetics   Hired: Ana Stanic as CFO, formerly EVP and CFO of Omrix Biopharmaceuticals Inc.  ...
08:00 , Jan 28, 2008 |  BC Week In Review  |  Company News

Aureon Laboratories Inc., Pfizer deal

The companies will use Aureon's integrated systems pathology approach to establish quantitative biometrics for assessing prostate cancer patients' therapeutic response to neo-adjuvant androgen deprivation therapy (ADT). Ownership of resulting IP will be determined by inventorship,...